bonaxon 0,5 mg kapsułki twarde
egis pharmaceuticals plc - fingolimodum - kapsułki twarde - 0,5 mg
golpimec 0,5 mg kapsułki twarde
neuraxpharm arzneimittel gmbh - fingolimodum - kapsułki twarde - 0,5 mg
lumykras
amgen europe bv - sotorasib - rak, niedrobnokomórkowe płuca - Środki przeciwnowotworowe - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.
fingolimod reddy 0,5 mg kapsułki twarde
reddy holding gmbh - fingolimodi hydrochloridum - kapsułki twarde - 0,5 mg
jaypirca
eli lilly nederland b.v. - pirtobrutinib - chłoniak, mantle-cell - inhibitory białka kinazy - treatment of mantle cell lymphoma (mcl).
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. efekt imatinib na wynik przeszczepienia szpiku kostnego nie jest określona. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. doświadczenie z imatinibom u pacjentów z mds/jest msy, związanych z pdgfr genów permutacji-bardzo ograniczony. brak kontrolowanych badań wykazują kliniczną korzyść lub zwiększone tempo dla tych chorób.
zelboraf
roche registration gmbh - wemurafenib - czerniak - Środki przeciwnowotworowe - wemurafenib jest wskazany w monoterapii w leczeniu dorosłych pacjentów z mutacją nieoperacyjną lub przerzutowym czerniaka braf-v600.
fingolimod alvogen 0,5 mg kapsułki twarde
zentiva, k.s. - fingolimodum - kapsułki twarde - 0,5 mg
fenoxa 0,5 mg kapsułki twarde
zakłady farmaceutyczne polpharma s.a. - fingolimodum - kapsułki twarde - 0,5 mg
fingolimod glenmark 0,5 mg kapsułki twarde
glenmark pharmaceuticals s.r.o. - fingolimodum - kapsułki twarde - 0,5 mg